arrow
C

Charalampos S. Floudas

national institutes of health
H指数:18
被引数:1,893

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immune checkpoint inhibitors in platinum-resistant ovarian Cancer: Clinical disappointments, biological lessons, and the reopening of therapeutic opportunities

免疫检查点抑制剂在铂耐药卵巢癌中的应用:临床失望、生物学启示以及治疗机会的重新开启

2026-10-240
PRE
Baseline and early changes in serum proteomic profiles predict anti-tumor activity in patients with advanced HPV-associated malignancies treated with novel combination immunotherapy

基线和早期血清蛋白质组学特征变化可预测接受新型联合免疫疗法治疗的晚期HPV相关恶性肿瘤患者的抗肿瘤活性

2026-10-210
OAAI
The Molecular and Immunological Landscape in Nasopharyngeal Carcinoma (NPC) Differs by Somatostatin Receptor 2 (SSTR2) Expression

鼻咽癌(NPC)中分子和免疫景观因生长抑素受体2(<i>SSTR2</i>)表达而异

2026-09-300
OAAI
Spatial cellular order underlies locally-confined mechanisms of immune resistance in oropharyngeal cancer

口咽癌中空间细胞有序性构成了局部限制性免疫抵抗机制的基础

2026-06-130
OAAI
The quadruple immunotherapy for colorectal cancer (QuICC) trial for mismatch repair-proficient metastatic colorectal cancer

针对错配修复 proficient 的转移性结直肠癌的四联免疫疗法(QuICC)试验

2026-03-012
PRE
Bridging the gap: A systematic approach to integrating serum and plasma proteomic datasets for biomarker studies

弥合差距:一种整合血清和血浆蛋白质组学数据集用于生物标志物研究的系统性方法

2026-02-010
OAAI
Genomic and Immune Correlates of EZH2 Expression and Activity in Olfactory Neuroblastoma

EZH2表达和活性的基因组与免疫相关性在嗅神经母细胞瘤中的研究

2025-11-010
OAAI
Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023)

癌症临床试验中与FDA药物审批相关的患者入组标准及基线特征(2009–2023)

2025-06-260
OA
PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer

PRGN-2009和bintrafusp alfa用于晚期或转移性人乳头瘤病毒相关癌症患者

2025-03-210
OA
Tri-Ad5 vaccine plus bintrafusp alfa for newly diagnosed, advanced-stage head and neck cancer not associated with human papillomavirus infection

Tri-Ad5疫苗联合bintrafusp alfa治疗新诊断、晚期且与人乳头状瘤病毒感染无关的头颈部癌症

2025-03-010
PRE
Performance status restrictions in clinical trials leading to US food and drug administration (FDA) drug approval: A cross-sectional study of a decade (2014-2023)

临床 trials 中 performance status 限制与 US food and drug administration (FDA) 药物审批的关系:一项跨越十年(2014-2023)的横断面研究

2024-09-010
PRE